Advancing Rapid Testing Standards

Nanogen is advancing the Point of Care industry with leading-edge Rapid Testing products. The company was awarded the contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a unique multi-analyte Point of Care diagnostic assay for Influenza. Nanogen is building on its proprietary technology to develop a low cost, high sensitivity Point of Care immunoassay that simultaneously detects Influenza Type A, Type B, seasonal flu and avian flu in a simple to use assay format.

Nanogen Wins CDC Contract to Develop Avian Flu Diagnostic
http://www.nanogen.com/presscenter/pressreleases/3167/

CDC Awards $11.4 Million to Develop New Rapid Diagnostic Tests for Avian Influenza
http://www.cdc.gov/od/oc/media/pressrel/r061204.htm?s_cid=mediarel_r061204_x

In addition, we are involved with leading industry organizations that are setting Point of Care testing standards. Nanogen currently has active roles in The Society of Chest Pain Centers and CLIA.

• http://www.scpcp.org
• http://www.fda.gov/cdrh/clia/